National Contact Point LIFESCIHEALTH Dr. Wilfried Diekmann Königswinterer Str. 522-524, 53227 Bonn

1. ERA-NET PathoGenoMics 2nd NSC & 3rd EB Meeting, April 07, 2005 Strategic supporting measures to raise synergies with the European framework programmes and to embed PathoGenoMics into the European R&D Landscape National Contact Point LIFESCIHEALTH Dr. Wilfried Diekmann Königswinterer Str. 522-524, 53227 Bonn phone: +49 228 447 698, e-mail: wilfried.diekmann@dlr.de http://www.nks-lebenswissenschaften.de

2. a) Application-orientated genomic approaches Brain and diseases of the nervous system Cardiovascular disease, diabetes and rare diseases Human development and the ageing process Resis- tance to antibiotics and other drugs b) Application of knowledge and technologies in the field of genomics and biotechnology for health TP 1 Life Science, Genomics and Biotechnology for Health Programme structure and pathogenomics-relevant areas i) Advanced Genomics and its applications for health a) Fundamental knowledge & basic tools for functional genomics in all organisms Comparative genomics and population genetics Multidisciplinary functional genomics approaches to basic biological processes Gene expression and proteomics Bio-informatics Structural genomics Innovative research in post-genomics with high potential for application New preventive and therapeutic tools (somatic gene and cell therapies; stem cell and immunotherapies, etc.) New in vitro tests to replace animal experimentation New, safer,more effective drugs (incl. pharmaco-genomics) New diagnostics ii) Combating major diseases c) Poverty- related diseases b) Cancer • HIV / AIDS • Malaria • Tuberculosis

3. 3rd Call (FP-2004-LIFESCIHEALTH-5, deadline: 16.11.2004) Selected pathogenomics-relevant areas

4. FP6 project portfolio in pathogenomics Pathogenomics-relevant proposals to the 3rd Call 10 2 * based on panel priority lists, i.e. major priority lists of COM services are not yet available

5. FP6 project portfolio in pathogenomics TP LSH, Fundamental Genomics, Outcome 3rd Call STREP Non-coding RNAs in bacterial pathogenicity (BACRNAs) Major Priority List; Coordinator: University of Vienna, AT CA Strategy to build up and maintain an integrated sustainable European fungal genomic database required for innovative genomics research on filamentous fungi important for biotechnology and human health (EUROFUNGBASE) Major Priority List; Coordinator: Universiteit Leiden, NL

6. Major Priority ? Reserve List ? FP6 project portfolio in pathogenomics TP LSH, Major Diseases, Outcome 3rd Call NoE Genomics to Combat Resistance against Antibiotics in Community-acquired Lower Respiratory Tract Infections in Europe (GRACE) NI Panel Priority Order 10; Coordinator: Universiteit Antwerpen; BE STREPs Combating resistance to antibiotics (CORANIX) TI Panel Priority Order 7; Coordinator: Institut Pasteur, FR Effects of antibiotic resistance on bacterial fitness, virulence and transmission (EAR) TI Panel Priority Order 9; Coordinator: Uppsala University, SE Role of Mobile Genetic Elements in the Spread of Antimicrobial Drug Resistance (DRESP2) TI Panel Priority Order 10; Coordinator: Universita degli Studi di Siena, IT Functional genomic characterisation of molecular determinants for staphylococcal fitness, virulence and drug resistance (StaphDynamics) TI Panel Priority Order 16; Coordinator: University of Groningen, NL

7. FP6 project portfolio in pathogenomics TP LSH, Major Diseases, Outcome 3rd Call Further STREPs passed the threshold: Antifungal drug resistance in the human pathogen Candida glabrata (ANTIGLA) TI Panel Priority Order 18; Coordinator: Instituto Superior Técnico, PT Combating Candida drug resistance, CDR, by novel drugs especially acting through interference with CDR regulatory network (CombatingCDR) TI Panel Priority Order 19; Coordinator: Universität Bonn, DE Factors affecting transfer and mobilization of extended spectrum beta- lactamases (MOBILACT) TI Panel Priority Order 21; Coordinator:University of Warwick, UK ADaptation of VANComycin-resistant Enterococci and Staphylococci: Ecological determinants of fitness and virulence (ADVANCES) TI Panel Priority Order 22; Coordinator: University Medical Centre Utrecht, NL Control of Resistance in Invasive Fungal Infection and Diagnosis (CRIFID) TI Panel Priority Order 23; Coordinator: University Medical Centre Nijmegen, NL Role of Genetic and Molecular Determinants in Survival and Spread of Foodborne Antibiotic Resistant Bacteria (FoodRBug) TI Panel Priority Order 25; Coordinator: University of Birmingham, UK

8. FP6 project portfolio in pathogenomics TP LSH, Major Diseases (Cancer), Outcome 3rd Call IPs The role of chronic INfections in the development of CAncer (INCA) NI Panel Priority Order 3; Coordinator: Medizinische Hochschule Hannover, DE Linking Cancer Transcriptome to Proteome: Functional Oncogenomics for Diagnosis and Treatment of Human Cancers related to Infectious Agents (EUROVIRC) NI Panel Priority Order 12; Coordinator: Fondazione Andrea Cesalpino, IT

9. FP6 project portfolio in pathogenomics TP LSH, Poverty-related diseases (i.e. tuberculosis), Outcome 3rd Call IPs New medicines for tuberculosis (NM4TB) NI Panel Priority Order 1; Coordinator: Institut Pasteur, FR A Consortium for Tuberculosis Drug Development (TB-DD) NI Panel Priority Order 7; Coordinator: University of Zürich, CH STREPs Innate and adaptive immunity in clinical and experimental mycobacterial infection in neonates and infants (NEOTIM) TI Panel Priority Order 5; Coordinator: Karolinska Institutet, SE New drugs for persistent tuberculosis: Exploitation of 3-D structure of novel targets, lead optimisation and functional in vivo evaluation (NewTBDrugs) TI Panel Priority Order 6; Coord.: LIONEX Diagnostics & Therapeutics GmbH, DE

10. Framework Programme 6, LIFESCIHEALTH Fundamental Genomics, Topics for 4th Call Gene expression and proteomics A systems approach to understanding the regulation of gene transcription – IP Structural genomics Structural genomics interdisciplinary initiative – IP Comparative genomics and population genetics Functional genomics in Arabidopsis thaliana - IP High throughput phenotyping tools and approaches for large scale functional genomics studies – IP Population cohorts for molecular epidemiological studies in European populations – IP Multidisciplinary functional genomics approaches to basic biological processes Functional genomics of autosomal aneuploid syndromes - IP The biological role of small regulatory RNAs - IP Specific Support Actions (SSAs) Co-ordination Actions (CA) Tools and technologies for functional genomics – STREP dedicated to SMEs

11. Framework Programme 6, LIFESCIHEALTH Biotech & Applied Genomics, Topics for 4th Call New, safer, more effective drugs including pharmacogenomics Marker profiling as a new tool for predictive toxicology - IP New tools to investigate ADME properties of drugs involving a carrier system – STREP New diagnostics High throughput molecular diagnostics for hereditary diseases - IP Development of innovative methods for diagnosis of nervous system disorders – STREP Nanoparticles-based diagnostics – STREP New in vitro tests to replace animal experimentation Predictive in vitro testing strategies for human exposure to chemicals - IP Workshop on business opportunities for in vitro pharmaceutical toxicology – SSA Researchers and regulators meet manufacturers of toxicology test methods – SSA New preventive & therapeutic tools, somatic gene and cell therapies, stem cells, immunotherapies Tissue engineering approaches to treating children with birth defects - IP Hepatitis C vaccine - IP Stem Cell Therapy for Stroke Patients – STREP Methodological research to underpin stem cell banking - STREP Use of baculovirus as a vector in gene therapy – STREP towards SME Innovative research in post-genomics, which has high potential for application Application of post-genomics to xenotransplantation research – IP Approaches exploiting aquatic molecular biodiversity for biomedical applications - IP Use of cell lines to define new bioassays for the identification of therapeutic biomolecules – STREP to SME All areas – STREP dedicated to SMEs

12. Framework Programme 6, LIFESCIHEALTH Major Diseases, Topics for 4th Call A) APPLICATIONS-ORIENTATED GENOMIC APPROACHES General (overarching) Genetic control of the pathogenesis of diseases based on iron metabolism – STREP Combating, cardiovascular disease, diabetes and rare diseases Genomic-wide mapping and functional genomics of susceptibility to coronary artery disease – IP Hypertension and cardiovascular disease – NOE Prevention of accelerated cardiovascular death in uraemia and end-stage renal disease - STREP Functional genomics and regulatory networks in lipid metabolism & their effects on atherogenic vascular disease development - STREP Gene-environment interaction on the incidence of type 2 diabetes - IP Molecular pathways underlying decreased beta cell mass in diabetes mellitus – STREP Rare inherited neuromuscular disorders: from molecular basis to cutting edge therapies - NOE Rare disorders of protein folding – STREP Rare diseases of connective tissues affecting bone and/or cartilage – STREP Research on cardiovascular and/or cerebrovascular disease – STREP towards SME Preventive and therapeutic strategies for Type 1 diabetes – STREP towards SME Development of in vitro and/or animal models for rare diseases – STREP towards SME

13. Framework Programme 6, LIFESCIHEALTH Major Diseases, Topics for 4th Call Combating resistance to antibiotics and other drugs Control of antimicrobial resistance in hospital acquired and health care associated infections – IP Molecular ecology of antibiotic drug resistance – IP Workshop exploring novel opportunities towards vaccines and control of anti-bacterial resistance - SSA New diagnostic tests for the management & control of antimicrobial resistance – STREP towards SME Novel principles for anti-microbial treatment – STREP towards SME Studying the brain and combating diseases of the nervous system Functional genomics and neurobiology of epilepsy – IP Neuroimaging: “Bridging genetics and neural function” – IP Cortical information processing – STREP Schizophrenia: from genotype to phenotype – STREP Initiative in neuroinformatics – SSA Neuroscience-oriented new technologies – STREP towards SME Animal models for neurological and psychiatric diseases – STREP towards SME Early markers and new targets for neurodegenerative diseases – STREP towards SME Perinatal brain damage: early markers and neuroprotection – STREP towards SME Studying human development and the ageing process Integration of research in development and ageing - NOE Attracting researchers to ageing research - SSA Responsiveness of elderly people towards vaccination and infectious diseases – STREP towards SME

14. Framework Programme 6, LIFESCIHEALTH Major Diseases (Cancer), Topics for 4th Call COMBATING CANCER Modulation of apoptosis in cancer prevention and therapy – IP Broadening the knowledge base on the molecular mechanisms underlying chemotherapy resistance, therapeutic escape, efficacy and toxicity – IP Early diagnosis and novel therapies of solid childhood cancers – STREP Innovative research on palliative care in patients with advanced stages of cancer – STREP Role of chromosomal aberrations and epigenetic mechanisms of leukaemia – STREP Identification and validation of biomarkers in molecular cancer epidemiology – STREP Exploring the patient’s cancer stem cell as a novel therapeutic target – STREP Conference on cell differentiation, plasticity and cancer – SSA Innovative technological approaches for cancer therapy – STREP towards SMEs Small-ligand libraries: improved tools for exploration and prospective anti-tumor therapy - STREP towards SMEs Improving resolution of current imaging devices relevant to cancer diagnosis and therapy - STREP towards SMEs Application of “molecular signatures” for the early diagnosis of cancer patients - STREP towards SMEs

15. Framework Programme 6, LIFESCIHEALTH Poverty-related diseases (PRD), Topics for 4th Call CONFRONTING THE MAJOR COMMUNICABLE DISEASES LINKED TO POVERTY HIV/AIDS Therapeutic Clinical trials network - NOE HIV/AIDS Vaccines/Microbicides Network - NOE Rationale Design of Malaria Vaccine - IP New approaches for research into host/vector-pathogen interaction for HIV/AIDS, malaria and tuberculosis – STREP Undesirable consequences of drugs and vaccines for Poverty-related Diseases – STREP Integration & coordination of European clinical research on PRD - SSA/CA Promotion of PRD research - SSA/CA European Network for vaccine development covering the three diseases - SSA/CA Improving participation of the private sector in PRD research – SSA towards SME SME-driven innovations for poverty related diseases – STREP towards SME Development of fast tests for diagnosis of poverty related diseases suitable for use in resource-poor settings – STREP towards SME Innovative delivery mechanism for treatment and depot therapy in Poverty-related diseases – STREP towards SME

16. Framework Programme 6, LIFESCIHEALTH Specific Support Actions across TP1; Topics for 4th Call Promoting Collaboration between SMEs and Academia Stimulating international co-operation Promotion of cooperation with Associated Candidate Countries (ACC) Realising ERA objectives Life sciences and biotechnology – A strategy for Europe. Supporting policy development Scientific and project management Mapping and identifying research efforts and contributions from FPs in the context of the European Community’s Public Health Programme, in the fields of health information, health threats and health determinants, with particular regard to mental health, reducing health risks, and preventing major as well as specific diseases. Mapping and identifying research efforts and contributions from FPs in the context of the European Environment and Health Action Plan, in the fields of gene-environment interactions, respiratory diseases, neuro-developmental disorders, cardiovascular diseases and cancers, with particular regard to children’s health Foresight study in the area of biotechnology and health European human embryonic stem cell registry